| Identification | Back Directory | [Name]
GDSKPIAEYNJODX-UHFFFAOYSA-N | [CAS]
1331942-30-3 | [Synonyms]
GSK5852
GSK-5852
GSK 5852
GDSKPIAEYNJODX-UHFFFAOYSA-N
(4-((N-(5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)-benzofuran-6-yl)methylsulfonamido)methyl)-2-fluorophenyl)-boronic acid
Boronic acid, B-[4-[[[5-cyclopropyl-2-(4-fluorophenyl)-3-[(methylamino)carbonyl]-6-benzofuranyl](methylsulfonyl)amino]methyl]-2-fluorophenyl]- | [Molecular Formula]
C27H25BF2N2O6S | [MDL Number]
MFCD28963892 | [MOL File]
1331942-30-3.mol | [Molecular Weight]
554.37 |
| Hazard Information | Back Directory | [Uses]
GSK5852 (GSK2485852) is an HCV NS5B polymerase inhibitor, with an IC50 value of 50 nM. GSK5852 displays antiviral activity and inhibits HCV with EC50s of 3.0 nM (genotype 1a, GT1a) and 1.7 nM (GT1b), respectively[1][2][3]. | [References]
[1] Zhou Z, et al. Small molecule NS5B RdRp non-nucleoside inhibitors for the treatment of HCV infection: A medicinal chemistry perspective. Eur J Med Chem. 2022 Jul 8. 240:114595. DOI:10.1016/j.ejmech.2022.114595
[2] Voitenleitner C, et al. In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother. 2013 Nov;57(11):5216-24. DOI:10.1128/AAC.00874-13
[3] Maynard A, et al. Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase. J Med Chem. 2014 Mar 13;57(5):1902-13. DOI:10.1021/jm400317w |
|
|